SCHOTT Pharma AG & Co. KGaA Total Assets
SCHOTT Pharma AG & Co. KGaA total assets. Based on the latest financial reports, SCHOTT Pharma AG & Co. KGaA (1SXP) holds total assets worth €1.44 Billion EUR (≈ $1.69 Billion USD) as of September 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 1SXP market cap for the company's overall valuation and market capitalisation.
Total Assets of SCHOTT Pharma AG & Co. KGaA (2020–2024)
Total assets of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024. This chart illustrates how SCHOTT Pharma AG & Co. KGaA's total assets have evolved over time, based on quarterly financial data. See today's stock price for SCHOTT Pharma AG & Co. KGaA for real-time trading data and today's change.
SCHOTT Pharma AG & Co. KGaA - Asset Composition Analysis
SCHOTT Pharma AG & Co. KGaA Total Assets Breakdown (June 2024)
SCHOTT Pharma AG & Co. KGaA total assets breakdown as of June 2024. SCHOTT Pharma AG & Co. KGaA's total assets of €1.44 Billion consist of 40.8% current assets and 59.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 1.6% |
| Accounts Receivable | €174.89 Million | 12.1% |
| Inventory | €140.44 Million | 9.7% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.12 Million | 0.1% |
| Goodwill | €29.35 Million | 2.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how SCHOTT Pharma AG & Co. KGaA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore SCHOTT Pharma AG & Co. KGaA current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SCHOTT Pharma AG & Co. KGaA's current assets represent 40.8% of total assets in 2024, an increase from 40.1% in 2020.
- Cash Position: Cash and equivalents constituted 1.6% of total assets in 2024, down from 3.1% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 4.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 12.1% of total assets.
SCHOTT Pharma AG & Co. KGaA Competitors by Total Assets
Key competitors of SCHOTT Pharma AG & Co. KGaA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Gan & Lee Pharmaceuticals Co Ltd
SHG:603087
|
China | CN¥12.76 Billion |
|
Andon Health Co Ltd
SHE:002432
|
China | CN¥29.91 Billion |
|
Caina Technology Co. Ltd.
SHE:301122
|
China | CN¥2.26 Billion |
|
QITIAN Technology Group Co Ltd
SHE:300061
|
China | CN¥1.17 Billion |
|
Visco Vision Inc.
TW:6782
|
Taiwan | NT$5.82 Billion |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK
|
Indonesia | Rp980.33 Billion |
|
Medeon Biodesign
TWO:6499
|
Taiwan | NT$1.55 Billion |
|
ZENTEK LTD.
F:ZAY0
|
Germany | €17.38 Million |
SCHOTT Pharma AG & Co. KGaA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.35 | 1.33 | 1.72 |
| Quick Ratio | 1.03 | 0.94 | 1.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €153.12 Million | €117.19 Million | €231.50 Million |
SCHOTT Pharma AG & Co. KGaA - Advanced Valuation Insights
This section examines the relationship between SCHOTT Pharma AG & Co. KGaA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.48 |
| Latest Market Cap to Assets Ratio | 1.66 |
| Asset Growth Rate (YoY) | 17.1% |
| Total Assets | €1.44 Billion |
| Market Capitalization | $2.39 Billion USD |
Valuation Analysis
Above Book Valuation: The market values SCHOTT Pharma AG & Co. KGaA's assets above their book value (1.66x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: SCHOTT Pharma AG & Co. KGaA's assets grew by 17.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SCHOTT Pharma AG & Co. KGaA (2020–2024)
The table below shows the annual total assets of SCHOTT Pharma AG & Co. KGaA from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €1.44 Billion ≈ $1.69 Billion |
+17.08% |
| 2023-06-30 | €1.23 Billion ≈ $1.44 Billion |
+2.95% |
| 2022-06-30 | €1.20 Billion ≈ $1.40 Billion |
+61.71% |
| 2021-06-30 | €739.89 Million ≈ $865.02 Million |
+24.14% |
| 2020-06-30 | €596.02 Million ≈ $696.81 Million |
-- |
About SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a… Read more